Use of Florbetapir-PET for Imaging -Amyloid Pathology
نویسندگان
چکیده
Christopher M. Clark, MD Julie A. Schneider, MD Barry J. Bedell, MD, PhD Thomas G. Beach, MD, PhD Warren B. Bilker, PhD Mark A. Mintun, MD Michael J. Pontecorvo, PhD Franz Hefti, PhD Alan P. Carpenter, PhD Matthew L. Flitter, BA Michael J. Krautkramer, BS Hank F. Kung, PhD R. Edward Coleman, MD P. Murali Doraiswamy, MD Adam S. Fleisher, MD, MAS Marwan N. Sabbagh, MD Carl H. Sadowsky, MD Eric M. Reiman, MD Simone P. Zehntner, PhD Daniel M. Skovronsky, MD, PhD for the AV45-A07 Study Group
منابع مشابه
Correlation between two methods of florbetapir PET quantitative analysis.
This study evaluated performance of a commercially available standardized software program for calculation of florbetapir PET standard uptake value ratios (SUVr) in comparison with an established research method. Florbetapir PET images for 183 subjects clinically diagnosed as cognitively normal (CN), mild cognitive impairment (MCI) or probable Alzheimer's disease (AD) (45 AD, 60 MCI, and 78 CN)...
متن کاملPET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
BACKGROUND Biomarkers based on the underlying pathology of Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB) have the potential to improve diagnosis and understanding of the substrate for cognitive impairment in these disorders. The objective of this study was to compare the patterns of amyloid and dopamine PET imaging in patients with AD, DLB and Parkinson's disease (PD) using the a...
متن کاملUse of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation.
BACKGROUND AND PURPOSE Fluorine-18 florbetapir is a recently developed β-amyloid plaque positron-emission tomography imaging agent with high sensitivity, specificity, and accuracy in the detection of moderate-to-frequent cerebral cortical β-amyloid plaque. However, the FDA has expressed concerns about the consistency of interpretation of [(18)F] florbetapir PET brain scans. We hypothesized that...
متن کاملThe use of amyloid imaging in clinical praxis: a critical review
Recent development in molecular imaging enables measurement of fibrillar amyloid plaque in Alzheimer (AD) brain using positron emission tomography (PET). Three tracers (florbetapir, flutemetamol, florbetaben) have been approved by FDA and EMA for use in clinical assessment of memory impairment to exclude AD. The use of amyloid PET imaging is considered to be appropriate in patients with persist...
متن کاملTechnical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
Technical factors play a critical role in the production of best-quality amyloid PET images for interpretation. This article provides specific instructions and general technical information about PET brain scanning of β-amyloid neuritic plaques. The focus of tracer-specific information will be on (18)F-florbetapir (indications, contraindications, dosing, administration, uptake time, scanning ti...
متن کاملNeuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
Neuropathologic heterogeneity is often present among Alzheimer disease (AD) patients. We sought to determine whether amyloid imaging measures of AD are affected by concurrent pathologies. Thirty-eight clinically and pathologically defined AD and 17 nondemented patients with quantitative florbetapir F-18 (F-AV-45) positron emission tomography (PET) imaging during life and postmortem histological...
متن کامل